News

Servier committed to working with NICE to ensure timely re-evaluation of Osteoporosis Guidance
20/03/2009

Following the successful Judicial Review instigated by Servi...

HIGH COURT VICTORY FOR OSTEOPOROSIS PATIENTS. NICE guidance to be re-evaluated in light of court ruling
19/02/2009

Servier Laboratories Limited, the licence holder of Protelos...

High Court of Justice Judgment - Media Statement
09/10/2008

Servier is disappointed by the decision of the English High ...

Media Statement: Perindopril Arginine
01/04/2008

As of 1 April 2008 perindopril’s tert-butylamine salt will b...

Statement on the Safety of Protelos (strontium ranelate)
16/11/2007

As part of its continuous monitoring of medicines, the Europ...

Trial stops after stroke and mortality significantly reduced by blood pressure-lowering treatment for those aged 80 and over
08/08/2007

An international trial looking at the benefits of giving blo...

Servier announced Corporate Supporter of the Year by Stroke Association
02/08/2007

Servier Laboratories have been awarded the Corporate Support...

Servier Cardiovascular Franchise celebrates PMEA Success
15/01/2007

Servier Laboratories have been announced the winners of the ...

Servier Laboratories Ltd has taken the decision to cease production of Aerodiol® (estradiol hemihydrate) Nasal Spray solution
20/12/2006

Servier Laboratories Ltd has taken the decision to cease pro...

Servier and Plexxikon signed Cardiovascular Collaboration
06/11/2006

NEUILLY, France and BERKELEY, Calif. – October 2, 2006 - Ser...

Servier launch new Product Website
02/11/2006

www.protelos.co.uk -...

Servier Laboratories and Alantos Pharmaceuticals announce collaboration in Type 2 diabetes
30/10/2006

Servier Laboratories and Alantos Pharmaceuticals have announ...

Servier Announce £132/€185 Million Irish Manufacturing Investment and New Research Partnership
27/10/2006

London, 27 October 2006: Servier, the leading French indepen...

Servier Laboratories join the ABPI
19/10/2006

The ABPI Board of Management have announced the new membersh...

Servier Announces Research and Best Practice Awards Winners
06/09/2006

French researched-based pharmaceutical company, Servier Labo...

Servier and Novartis sign licensing agreement for agomelatine, a novel treatment for depression
29/03/2006

Servier and Novartis announced today the signing of a licens...

Osteoporosis: Delivering Osteoporosis Services in Primary Care…
27/03/2006

An innovative and stimulating new online educational tool fo...

Pharmaceutical Marketing Effectiveness Awards 2005 - Servier wins three Awards
14/12/2005

Servier Laboratories won three prestigious Pharmaceutical Ma...

Servier Launches Research and Best Practice Awards
13/10/2005

French researched-based pharmaceutical company, Servier Labo...

Breakthrough osteoporosis treatment, Protelos, receives prestigious Frost & Sullivan Award for Innovation
04/08/2005

San Francisco & Paris, March 16th 2005: Frost & Sullivan, th...

Servier unveils New Multi-million Pound UK Laboratory
01/07/2005

The UK subsidiary of the independent, research-based French ...

Protelos® significantly reduces non vertebral fracture risk in postmenopausal women with osteoporosis
14/06/2005

The results of the TROPOS (Treatment of Peripheral Osteoporo...

SERVIER is awarded the Prix Galien 2005 for PROTELOS in France
08/06/2005

Paris, June 2nd 2005: PROTELOS® (strontium ranelate) has jus...

SERVIER strengthens its commitment to diabetes by collaborating in the EURADIA programme
09/02/2005

The European Research Area in Diabetes Diabetes in all it...